Evidence map›Paper›PMID 29069464›Full record

ReviewNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2019

Sleep as a Target for Optimized Response to Smoking Cessation Treatment.

Freda Patterson, Michael A Grandner, Susan K Malone, Albert Rizzo, Adam Davey, David G Edwards

Open access · bronzeAbstract readReview
In one paragraph

Review in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Freda PattersonCollege of Health Sciences, University of Delaware, Newark, DE.
Michael A GrandnerSleep and Health Research Program, Department of Psychiatry, University of Arizona College of Medicine, Tucson, AZ.
Susan K MaloneCenter for Sleep and Circadian Neurobiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Albert RizzoChristiana Care Health System, Pulmonary and Critical Care Medicine, Newark, DE.
Adam DaveyCollege of Health Sciences, University of Delaware, Newark, DE.
David G EdwardsCollege of Health Sciences, University of Delaware, Newark, DE.
University of Delaware · USChristiana Care Health System · USUniversity of Arizona · USUniversity of Pennsylvania · US

Funding

Vascular Consequences of Duchenne Muscular DystrophyP20GM113125 · NIGMS · UNIVERSITY OF DELAWARE · PI FANCHER, IBRA · 2016 to 2025
$23.3M
P20 Exploratory Center for Precision Health in Diverse PopulationsP20NR018075 · NINR · NEW YORK UNIVERSITY · PI BRODY, ABRAHAM AIZER · 2018 to 2022
$1.9M
Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults with Pre-DiabetesK99NR017416 · NINR · NEW YORK UNIVERSITY · PI MALONE, SUSAN KOHL · 2018 to 2019
$180k
NIGMS NIH HHS P20 GM113125NINR NIH HHS K99 NR017416NINR NIH HHS P20 NR018075
6 · The paper itself

Abstract

Declining national rates of current tobacco use to an all-time low of 15.1% represents a public health victory. Undermining this progress, however, are smoking rates of up to 50% among high-risk, low-income populations. Current FDA-approved treatments for nicotine dependence are ineffective with between 70-95% of treatment-seekers relapsing within the first year of attempted abstinence. Thus, identification of novel intervention targets to optimize response to currently available treatments for nicotine dependence is a critical next step. One such target may be sleep insomnia. Insomnia is a clinically verified nicotine withdrawal symptom but, to date, addressing insomnia or other sleep disturbance symptoms as an adjunctive smoking cessation therapy has yet to be fully considered. To this end, this manuscript presents a narrative review of: (1) sleep continuity and architecture in smokers versus nonsmokers; (2) effects of nicotine abstinence on sleep; (3) possible mechanisms linking sleep with smoking cessation outcomes; (4) plausible adjunctive sleep therapies to promote smoking cessation; (5) possible treatments for unhealthy sleep in smokers; and (6) directions for future research. Taken together, this will provide conceptual support for sleep therapy as an adjunctive treatment for smoking cessation. Implications: This narrative literature review presents a comprehensive discussion of the relationship between habitual sleep and cigarette smoking. The extent to which unhealthy sleep in smokers may be a viable intervention target for promoting response to smoking cessation treatment is considered. Ultimately, this review provides conceptual support for sleep therapy as an adjunctive treatment for smoking cessation.

Indexed as

HumansPovertySleep StagesSleep Wake DisordersSmokingSmoking CessationSubstance Withdrawal SyndromeTobacco SmokingTobacco Use Disorder

Identifiers

PMID29069464
PMCPMC6329404
OpenAlexW2765438996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.